Dordaviprone is a protease inhibitor used to treat diffuse midline glioma with a H3 K27M mutation. Dordaviprone is a first-in-class small molecule imipridone.
- Mechanism
- Curator reviewed · 8 references
Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP), a mitochondrial serine protease. Diffuse midline gliomas harboring an H3 K27M mutation are associated with the loss of H3 K27 trimethylation. In vitro, dordaviprone induced apoptosis and altered mitochondrial metabolism leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma models. Dordaviprone activates ATF4 and induces endoplasmic reticulum (ER) stress response or integrated stress response (ISR).
Dordaviprone also inhibits the dopamine D2 receptor, which are often overexpressed in multiple cancers, including glioblastoma.
- Primary indication
- Dordaviprone is indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.Curator reviewed · 1 structured indication
- Formula / weight
- C24H26N4O · 386.499 g/mol (avg)
- First approval
- United States, 2025
- Code names
- NSC-350625 · ONC-201 · TIC-10
- Brand names
Resolves to
VLULRUCCHYVXOH-UHFFFAOYSA-NSMILESCC1=CC=CC=C1CN1C2=NCCN2C2=C(CN(CC3=CC=CC=C3)CC2)C1=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Dordaviprone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account